• FDA Approves Pembrolizumab for Esophageal or GEJ Carcinoma americanpharmaceuticalreview
    March 26, 2021
    The U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck Sharp & Dohme Corp.) in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or ...
PharmaSources Customer Service